blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1602369

EP1602369 - Bupropion Metabolites for treating anxiety [Right-click to bookmark this link]
Former [2005/49]Bupropion Metabolites and Methods of their Synthesis and Use
[2009/22]
StatusNo opposition filed within time limit
Status updated on  11.02.2011
Database last updated on 03.10.2024
Most recent event   Tooltip28.09.2012Lapse of the patent in a contracting state
New state(s): LU		published on 31.10.2012  [2012/44]
Applicant(s)For all designated states
SEPRACOR, INC.
84 Waterford Drive
Marlborough, MA 01752 / US
[2010/14]
Former [2005/49]For all designated states
SEPRACOR, INC.
84 waterford Drive
Marlborough, MA 01752 / US
Inventor(s)01 / Fang, Qun, K
35 Atwood Street
02181, Wellesley / US
02 / Senanayake, Chrisantha, H
12 Isabel's Way
Brookfield, CT 06804 / US
03 / Grover, Paul
4 Warwick Road
02038, Franklin / US
 [2006/13]
Former [2005/49]01 / Fang, Qun, K
35 Atwood Street
02181, Wellesley / US
02 / Senanayake, Chrisantha, H
11 Old Farm Circle
01545, Shrewsbury / US
03 / Grover, Paul
4 Warwick Road
02038, Franklin / US
Representative(s)Killin, Stephen James, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[N/P]
Former [2005/49]Killin, Stephen James, et al
Venner Shipley LLP 20 Little Britain
London EC1A 7DH / GB
Application number, filing date05106426.923.08.2000
[2005/49]
Priority number, dateUS2000051024122.02.2000         Original published format: US 510241
US2000064072518.08.2000         Original published format: US 640725
[2005/49]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1602369
Date:07.12.2005
Language:EN
[2005/49]
Type: A3 Search report 
No.:EP1602369
Date:14.02.2007
[2007/07]
Type: B1 Patent specification 
No.:EP1602369
Date:07.04.2010
Language:EN
[2010/14]
Search report(s)(Supplementary) European search report - dispatched on:EP15.01.2007
ClassificationIPC:A61K31/5375, A61K31/137, A61P25/24, A61P25/34, A61P25/20
[2006/47]
CPC:
A61K31/537 (EP,US); A61K31/5375 (EP,KR,US); A61K31/00 (EP,US);
A61K31/135 (EP,US); A61K31/137 (EP,US); A61K31/165 (EP,US);
A61K31/415 (EP,US); A61K31/43 (EP,US); A61K31/435 (EP,US);
A61K31/46 (EP,US); A61K31/465 (EP,US); A61K31/50 (EP,US);
A61K31/53 (EP,US); A61K31/535 (EP,US); A61K45/06 (EP,US);
A61P1/08 (EP); A61P13/00 (EP); A61P13/10 (EP);
A61P15/00 (EP); A61P15/10 (EP); A61P25/00 (EP);
A61P25/04 (EP); A61P25/08 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/34 (EP); A61P43/00 (EP);
C07C213/00 (EP,US); C07C215/30 (EP,US); C07C225/16 (EP,US);
C07C45/511 (EP,US); C07C45/63 (EP,US); C07C49/84 (EP,US);
C07C69/76 (EP,US); C07D265/32 (EP,US); C07B2200/07 (EP,US) (-)
C-Set:
A61K31/135, A61K2300/00 (US,EP);
A61K31/137, A61K2300/00 (US,EP);
A61K31/165, A61K2300/00 (US,EP);
A61K31/415, A61K2300/00 (US,EP);
A61K31/435, A61K2300/00 (US,EP);
A61K31/43, A61K2300/00 (US,EP);
A61K31/465, A61K2300/00 (US,EP);
A61K31/46, A61K2300/00 (US,EP);
A61K31/50, A61K2300/00 (US,EP);
A61K31/535, A61K2300/00 (EP,US);
A61K31/5375, A61K2300/00 (EP,US);
A61K31/53, A61K2300/00 (EP,US);
C07C45/511, C07C49/82 (US,EP);
C07C45/63, C07C49/80 (US,EP)
(-)
Former IPC [2005/49]A61K31/137, A61P25/24, A61P25/34, A61P25/20, A61K31/5375
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2005/49]
Extension statesAL13.07.2005
LT13.07.2005
MK13.07.2005
RO13.07.2005
SI13.07.2005
TitleGerman:Bupropion Metaboliten zur Behandlung von Angstzuständen[2010/14]
English:Bupropion Metabolites for treating anxiety[2009/22]
French:Métabolites du bupropione pour traiter l'anxiété[2009/22]
Former [2005/49]Bupropion Metaboliten und Verfahren zu ihrer Synthese und Behandlung
Former [2005/49]Bupropion Metabolites and Methods of their Synthesis and Use
Former [2005/49]Métabolites du bupropione et méthodes pour leur synthèse et utilisation
Examination procedure13.07.2005Examination requested  [2005/49]
08.08.2007Despatch of a communication from the examining division (Time limit: M06)
27.12.2007Reply to a communication from the examining division
25.01.2008Despatch of a communication from the examining division (Time limit: M06)
20.11.2008Reply to a communication from the examining division
18.05.2009Communication of intention to grant the patent
18.11.2009Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
27.01.2010Fee for grant paid
27.01.2010Fee for publishing/printing paid
Parent application(s)   TooltipEP00957684.4  / EP1259243
Opposition(s)10.01.2011No opposition filed within time limit [2011/11]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
27.01.2010Request for further processing filed
27.01.2010Full payment received (date of receipt of payment)
Request granted
09.02.2010Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
20.11.2008Request for further processing filed
20.11.2008Full payment received (date of receipt of payment)
Request granted
10.12.2008Decision despatched
Fees paidRenewal fee
13.07.2005Renewal fee patent year 03
13.07.2005Renewal fee patent year 04
13.07.2005Renewal fee patent year 05
12.08.2005Renewal fee patent year 06
14.08.2006Renewal fee patent year 07
14.08.2007Renewal fee patent year 08
28.08.2008Renewal fee patent year 09
25.08.2009Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.04.2010
BE07.04.2010
DK07.04.2010
FI07.04.2010
IT07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
PT09.08.2010
IE23.08.2010
LU23.08.2010
MC31.08.2010
[2012/44]
Former [2011/36]AT07.04.2010
BE07.04.2010
DK07.04.2010
FI07.04.2010
IT07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
PT09.08.2010
IE23.08.2010
MC31.08.2010
Former [2011/15]AT07.04.2010
BE07.04.2010
DK07.04.2010
FI07.04.2010
IT07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
PT09.08.2010
MC31.08.2010
Former [2011/08]AT07.04.2010
DK07.04.2010
FI07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
PT09.08.2010
Former [2011/07]AT07.04.2010
DK07.04.2010
FI07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
Former [2011/03]AT07.04.2010
FI07.04.2010
SE07.04.2010
CY21.04.2010
GR08.07.2010
ES18.07.2010
Former [2011/01]AT07.04.2010
FI07.04.2010
SE07.04.2010
GR08.07.2010
ES18.07.2010
Former [2010/52]AT07.04.2010
FI07.04.2010
SE07.04.2010
ES18.07.2010
Former [2010/46]ES18.07.2010
Documents cited:Search[X]WO9937305  (GLAXO GROUP LTD [GB], et al) [X] 1-4,7-9,12,19,20,22-30 * page 1, line 1 - line 18 * * page 4, line 20 - page 5, line 29 * * page 2 - page 3 * * claims 1-6 *;
 [X]  - POLLOCK, B. G. ET AL, "Bupropion plasma levels and CYP2D6 phenotype", THER. DRUG MONIT. (1996), 18(5), 581-585, (1996), XP001040975 [X] 1-9,12,19,20,22-30,53-61 * page 582, column 2, paragraph 2 * * page 581, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1097/00007691-199610000-00010
 [X]  - MUSSO ET AL, "Synthesis and evaluation of the antidepressant activity of the enentiomers of bupropion", CHIRALITY, WILEY-LISS, NEW YORK, US, (1993), vol. 5, no. 7, ISSN 0899-0042, pages 495 - 500, XP002107656 [X] 1-9,12,19,20,22-30,53-61 * page 495, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1002/chir.530050704
 [X]  - PERUMAL, A. S. ET AL, "Down-regulation of.beta.-receptors by bupropion and its major metabolite in mouse brain", NEUROPHARMACOLOGY (1986), 25(12), 1323-6, (1986), XP001040976 [X] 1-9,12,19,20,22-30,53-61 * page 1323, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/0028-3908(86)90103-6
 [X]  - LAIZURE, S. CASEY ET AL, "Stability of bupropion and its major metabolites in human plasma", THER. DRUG MONIT. (1985), 7(4), 447-50, (1985), XP001040981 [X] 1-9,12,19,20,22-30,53-61 * page 447, column 1, paragraph 2 - column 2, paragraph 1 * * figure 1 *
 [X]  - KELLEY JAMES L ET AL, "-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: A novel antidepressant agent and selective inhibitor of norepinephrine uptake", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1996), vol. 39, no. 2, ISSN 0022-2623, pages 347 - 349, XP002164358 [X] 1-9,12,19,20,22-30,53-61 * page 347, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1021/jm950630p
 [PX]  - ADEOYE, O. M. ET AL, "Bupropion plasma concentration and antidepressant response in elderly patients: A prospective, randomized, double-blind study", INT. J. GERIATR. PSYCHOPHARMACOL. (2000), 2(3), 132-136, (2000), XP001040979 [PX] 1-9,12,19,20,22-30,54-61 * page 132, column 2, paragraph 3 *
Examination   - SIMON ET AL., "Bupropion sustained erelease for panic disorder", PSYCHOPHARMACOL. BULL. 2003; 37(4) 66-72
    - BYSTRITSKY ET AL., ""A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder".", PSYCHOPHARMACOL. BULL. 2008; 41(1) 46-51
by applicantJPS6391352B
 US3536809
 US3598123
 US3819706
 US3845770
 US3885046
 US3916899
 US4008719
 US4393078
 US4425363
 US4435449
 US4438138
 EP0118036
 US4507323
 US4571395
 US4624665
 US4655767
 US4687481
 US4797284
 US4798826
 US4810499
 US4835147
 US4895845
 US4917895
 US4927687
 US4935429
 US4956171
 US5059595
 US5073543
 US5091186
 US5120548
 US5163899
 US5217987
 US5232702
 US5234690
 US5273755
 US5273756
 US5308625
 US5354556
 US5356632
 US5358715
 US5358970
 US5372579
 US5421816
 US5447948
 US5466465
 US5494680
 US5505958
 US5541231
 US5554381
 US5560922
 US5585111
 US5591767
 US5639476
 US5656285
 US5667798
 US5674533
 US5698217
 US5731000
 US5733566
 US5741511
 US5747783
 US5753712
 US5763493
 US5770219
 US5814599
 US5817332
 US5833647
 US5879322
 US5906830
    - Physicians' Desk Reference®, (1999), pages 1252 - 1258
    - JUARISTI, E., Introduction to Stereochemistry & Conformational Analysis, JOHN WILEY AND SONS, INC., (1991), pages 144 - 151
    - ELIEL, E. L., Stereochemistry of Çarbon Compounds, MCGRAW-HILL, (1962), pages 49 - 53
    - ASCHER, J. A. ET AL., J. CLIN. PSYCHIATRY, (1995), vol. 56, pages 395 - 401
    - POSNER, J. ET AL., EUR. J: CLIN PHARMACAL., (1985), vol. 29, pages 97 - 103
    - SUCKOW, RF. ET AL., BIOMEDICAL CLUOMATOGRAPHY, (1997), vol. 11, pages 174 - 179
    - KELLEY, J. L. ET AL., J. MED. CHEM., (1996), vol. 39, pages 347 - 349
    - SUCKOW, R.F. ET AL., BIOMEDICAL CHROMATOGRAPHY, (1997), vol. 11, pages 174 - 179
    - POSNER, J. ET AL., EUR. J. CLIN. PHARNIACOL., (1985), vol. 29, pages 97 - 103
    - ROSE, J.E., ARMU. REV MED., (1996), vol. 47, pages 493 - 507
    - FERRY, L.H. ET AL., J. ADDICT. DIS., (1994), vol. 13, page A9
    - LIEF, H.I., AM. J. PSYCHIATRY, (1996), vol. 153, no. 3, page 442
    - Physicians' Desk Refererece®, (1999), pages 1252 - 1258
    - MUSSO ET AL., CHIRALITY, (1993), vol. 5, pages 495 - 500
    - WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
    - WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - BLIEL, E. L., Stereochemistry of Carbon Compounds, MCGRAW-HILL, (1962), pages 49 - 53
    - FITZI, R.; SEEBACH, D., ANGEW. CHEM. INT. ED., (1986), vol. 25, page 345
    - GHARPURE, M. M.; RAO, A. S., SYNTHESIS, (1988), page 410
    - MOISSET, B. ET AL., BRAIN RES., (1975), vol. 92, pages 157 - 164
    - JANOWSKY, A. ET AL., J NEUROCHEM, (1986), vol. 46, pages 1272 - 1276
    - PEROVIC, S.; MULLER, W. E. G., BRAIN RES., (1995), vol. 92, pages 157 - 164
    - JENS T. CARSTENSEN, Drug Stabiliy: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 80
    - JANOWSKY, A. ET AL., J NEUROCHEM., (1986), vol. 46, pages 1272 - 1276
    - PEROVIC, S.; MULLER, W. E.G., BRAIN RES., (1995), vol. 92, pages 157 - 164
    - GREEN; MURRAY, J. PHARM. PHARMACOL, (1989), vol. 41, pages 879 - 880
    - BANNON, A.W. ET AL., SCIENCE, (1998), vol. 279, pages 77 - 81
    - DUBUSSON, D.; DENNIS, S.G., SCIENCE, (1977), vol. 4, page 161
    - S.H. KIM; J.M. CHUNG, SCIENCE, (1992), vol. 50, page 355
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.